Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support

Journal of Clinical Oncology

Volumn 17, Issue 10, 1999, Pages 3064-3074

  Rizzieri, David A ^a   Vredenburgh, J J ^a   Jones, R ^a   Ross, M ^a   Shpall, E J ^a   Hussein, A ^a   Broadwater, G ^a   Berry, D ^a   Petros, W P ^a   Gilbert, C ^a   Affronti, M L ^a   Coniglio, D ^a   Rubin, P ^a   Elkordy, M ^a   Long, G D ^a   Chao, N J ^a   Peters, W P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032887240     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.10.3064     Document Type: Article

References (19)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics. CA Cancer J Clin 47:5-27, 1997
2. Chu KC, Tarone RE, Kessler LG, et al: Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 88:1571-1579, 1996
3. Greenberg PA, Hortobagyi GN, Smith TL, et al: Long term follow up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197-2205, 1996
4. Jones RB, Shpall EJ, Ross M, et al: AFM induction chemotherapy, followed by intensive alkylating agent consolidation with autologous bone marrow support (ABMS) for advanced breast cancer: Current results. Proc Am Soc Clin Oncol 9:9, 1990 (abstr 30)
5. Bezwoda WR, Seymour L, Dansey RD: High dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483-2489, 1995
6. Bezwoda WR: Primary high dose chemotherapy for metastatic breast cancer: Update and analysis of prognostic factors. Proc Am Soc Clin Oncol 17:115a, 1998 (abstr 445)
7. Peters WP, Jones RB, Vredenburgh JJ, et al: A large, prospective, randomized trial of high dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Br Cancer Res Treat 37:11, 1996 (suppl 35, abstr)
8. Cox DR: Regression models and life tables. J Royal Stat Soc B, 34:187-220, 1972
9. Davidoff AM, Kerns BJ, Iglehart JD, et al: Maintenance of p53 alterations throughout stages of breast cancer progression. Cancer Res 51:2605-2610, 1991
10. Peters WP, Ross M, Vredenburgh JJ, et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132-1143, 1993
11. Peters WP, Ross M, Vredenburgh JV, et al: High dose chemotherapy and autologous bone marrow support as consolidation after standard dose adjuvant therapy for high-risk primary breast cancer, in Salmon SE (ed): Adjuvant Therapy of Cancer VII. Philadelphia, PA, Lippincott, 1993, pp 207-213
12. Holmes FA, Valero V, Buzdar AU, et al: Final results: Randomized phase III trial of paclitaxel by 3 hour versus 96 hour infusion in patients with metastatic breast cancer - The long and short of it. Proc Am Soc Clin Oncol 17:110a, 1998 (abstr 426)
13. Sikov W, Akerler W, Strenger R, et al: Weekly high-dose paclitaxel demonstrates significant activity in advanced breast cancer (BC). Proc Am Soc Clin Oncol 17:112a, 1998 (abstr 432)
14. Ayash LJ, Wheeler C, Fairclough D, et al: Prognostic factors for prolonged progression-free survival with high dose chemotherapy with autologous stem cell support for advanced breast cancer. J Clin Oncol 13:2043-2049, 1995
15. Antman KA, Rowlings PA, Vaughan WP, et al: High dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America. J Clin Oncol 15:1870-1879, 1997
16. Bociek G, Reed E, Tarantolo S, et al: A comparative study of high dose chemotherapy/stem cell transplantation (HCSCT) versus standard chemotherapy (CT) in patients (PTS) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 17:114a, 1998 (abstr 440)
17. Dunphy FR, Spitzer G, Fornoff JER, et al: Factors predicting long term survival for metastatic breast cancer patients treated with high dose chemotherapy and bone marrow support. Cancer 73:2157-2167, 1994
18. Hu WW, Negrin RS, Stockerl-Goldstein KE, et al: Factors associated with the outcome for patients with stage IV breast cancer undergoing high dose chemotherapy with hematopoietic cell support. Proc Am Soc Clin Oncol 16:98a, 1997 (abstr 344)
19. Berruti A, Zola P, Buniva MG, et al: Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first line chemotherapy with epirubicin: Evidence for a positive effect of maintenance hormonal therapy on overall survival. Anticancer Res 17:2763-2768, 1997